Cardiometabolic Syndrome, Drug Interactions, LDL-Cholersterol Lowering, Primary Prevention
Conditions
Keywords
Statin intolerance, drug drug interaction, inclisiran, LDL-Cholesterol, polypharmacy, multiple comorbidities
Brief summary
Drug-drug interactions often limit statin optimization in a population of patients prescribed cytochrome P3A4 inhibitors, which include immunosuppressive agents, protease inhibitors, and antifungals. These patients frequently have autoimmune conditions or rheumatologic disorders that require complex drug regimens and are often on low-dose statin therapy or no statin at all, resulting in suboptimal LDL levels despite increased cardiovascular (CV) risk. There is an unmet clinical need to improve LDL levels in this vulnerable patient population, which faces increased CV risk due to underlying conditions that also contribute to polypharmacy and multiple drug-drug interactions. This study is a randomized, open-label trial evaluating subcutaneous inclisiran plus standard of care for LDL-C lowering in high-risk primary prevention patients with multiple comorbidities (e.g., Type II diabetes, liver disease, chronic kidney disease, autoimmune disease, solid-organ transplant) who are taking five or more medications in which drug-drug interactions prevent optimization of statin therapy.
Detailed description
This is an investigator-initiated, single-site, open-label, randomized trial. The investigators will enroll up to 100 high-risk primary prevention patients with at least one comorbidity and an indication for additional lipid control (such as Type II diabetes with A1c ≤ 8.5%, subclinical atherosclerosis, or ASCVD risk of 7.5% or greater). Patients will be randomized 1:1 to the inclisiran arm (n ≥ 50) with standard of care or standard of care alone (n ≥ 50). The study will consist of five study visits (screening, baseline, 3 months, 9 months, and 12 months). Patients in the inclisiran arm will receive a subcutaneous injection of inclisiran 284 mg for three doses (baseline, 3 months, and 9 months following randomization) as add-on therapy. LDL-C (the primary endpoint) along with other biomarkers will be measured at screening, baseline (inclisiran dose #1), 3 months (inclisiran dose #2), 9 months (inclisiran dose #3), and 12 months (labs only). Patients will also undergo medical history and medication review at each visit. Surveys will be completed at each visit during the study period. Patients in the control arm (standard of care) will continue with their current lipid-lowering therapy. No adjustments will be made to lipid-lowering therapy during the course of the study. Participants will be aware of the group to which they have been randomized. The primary objective is to determine the efficacy of inclisiran for LDL-C lowering in high-risk primary prevention patients with multiple comorbidities (e.g., Type II diabetes, autoimmune disease, liver disease, chronic kidney disease, solid-organ transplant) who are taking five or more medications in which drug-drug interactions prevent optimization of statin therapy.
Interventions
The intervention arm will receive subcutaneous injection of inclisiran 284mg at the baseline visit, 3 months and 9 month visit.
Sponsors
University of California, San Diego
Novartis
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Intervention model description
Patients will be randomized 1:1 to the inclisiran arm (n=50) or will continue with standard of care (n=50). The study will consist of 5 study visits (screening, baseline, 3 mo., 9 mo., and 12 mo.). Patients in the inclisiran arm will be treated with subcutaneous injection of inclisiran 284mg (baseline, 3 months, then 9 month visit) as add-on therapy to SOC lipid-lowering therapies. LDL-C (primary endpoint) along with other biomarkers will be measured at screening, baseline, 3 mo., 9 mo., and 12 months.
Eligibility
Sex/Gender
ALL
Age
18 Years to 85 Years
Healthy volunteers
No
Inclusion criteria
* Provision of signed and dated informed consent form. * Stated willingness to comply with all study procedures and availability for the duration of the study, including potential randomization to injections. * Age \>18 and \<85 years and able to provide self-consent. * Taking five or more prescription drugs at the time of enrollment, of any type. * Meets at least one of the following criteria: * Elevated 10-year ASCVD risk score ≥7.5% (based on the ACC/AHA ASCVD Risk Estimator Plus tool). * Evidence of subclinical atherosclerosis including: Calcification in any vascular bed, including coronary arteries and aorta. Calcification of cardiac valves. Breast calcification. Carotid plaque that is not hemodynamically significant. o Type II diabetes on a stable medical regimen with HbA1c \<8.5%. Per American Diabetes Association guidelines, patients with Type II diabetes aged 40-75 years should be on a moderate-intensity statin. Patients with documented partial or complete statin intolerance are eligible for enrollment. * On maximally tolerated statin therapy (which can be no statin for patients with documented intolerance) and have suboptimal LDL levels: * For patients with Type II diabetes: LDL \>70 mg/dL or non-HDL \>120 mg/dL. * For other patients: LDL \>90 mg/dL or non-HDL \>120 mg/dL. * Willing to adhere to the randomized study regimen, including subcutaneous injection of inclisiran. * Agreement to adhere to lifestyle considerations (see Section 5.3) throughout the study duration.
Exclusion criteria
* Prior or current use of inclisiran. * Known hypersensitivity or allergy to inclisiran or its components. * Active liver disease or unexplained persistent elevations in liver enzymes (ALT or AST \>3x upper limit of normal). * History of rhabdomyolysis or severe muscle-related statin intolerance. * Uncontrolled diabetes (HbA1c \>8.5%). * Active malignancy requiring systemic therapy. * Recent major cardiovascular event (myocardial infarction, stroke, or hospitalization for unstable angina) within the past 3 months. * History of organ transplant other than solid-organ transplant. * Pregnancy or breastfeeding. * Any condition that, in the opinion of the investigator, would make participation unsafe or interfere with study procedures.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change of LDL-Cholesterol | 12 months | Percent Change in LDL-C from baseline to month 12 of treatment with inclisiran as add on to background lipid-lowering therapy that includes maximally tolerated statin. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Change in Atherogenic Lipid Burden | 12 months | Absolute and percent change in LDL particle number, apo B, non-HDL, and small dense LDL, lipoprotein(a), from baseline (Visit 1) to month 12 of treatment with inclisiran |
Countries
United States
Contacts
CONTACTPam Taub, MD
CONTACTAntoinette S Birs, MD
STUDY_DIRECTORMichael Wilkinson, MD
University of California, San Diego
STUDY_CHAIREric D Adler, MD
University of California, San Diego
PRINCIPAL_INVESTIGATORPam Taub, MD
University of California, San Diego
STUDY_DIRECTORAntoinette Birs, MD
University of California, San Diego
Outcome results
None listed